Studying blood cell changes after CAR-T therapy for blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of multiple myeloma or a CD19-positive lymphoproliferative disorder (a type of blood cancer).
- You need to provide written consent to join the study.
- You must be willing to give bone marrow samples, hair follicles, skin biopsies (if at Mayo Clinic Rochester), saliva, and cheek swabs for research.
- You must be willing to have follow-up visits at the study site during the active monitoring period.
- You cannot have been diagnosed with a myeloid neoplasm (a different type of blood cancer) before receiving CAR-T therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.